For patients with hormone receptor-positive early breast cancer, the POSITIVE trial demonstrated that temporary interruption of endocrine therapy to attempt pregnancy did not confer a greater risk of breast cancer recurrence [28]. The gene discussed is NR4A1; the disease is breast carcinoma.